Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
Publications
4 records shown · first 60Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.
PMID 40732356 | PMCID PMC12299335 | DOI 10.3390/ph18071069 · Pharmaceuticals (Basel, Switzerland) · 2025 · 8 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | rs4149056 | “We evaluated the association of SLCO1B3 (rs4149117, rs7311358) and SLCO1B1 (rs2306283, rs4149056) polymorphisms with MTX efficacy and safety in Saudi patients with RA.” | 0.90 | hgvs_regex_v1 |
| gene | SLCO1B3 | “Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.” | 0.98 | hgnc_dict_v1 |
| gene | SLCO1B1 | “Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | rheumatoid arthritis | “Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.” | 0.98 | phenotype_alias_lexicon_v2 |
Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population.
PMID 38523294 | PMCID PMC10962151 | DOI 10.1186/s40246-024-00594-9 · Human genomics · 2024 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | rs4149056 | “RESULTS: We identified 141 previously described SNPs, of which rs2306283 (50%) and rs4149056 (28%), were the most common.” | 0.90 | hgvs_regex_v1 |
| gene | SLCO1B1 | “Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population.” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia | “Large-scale next generation sequencing based analysis of SLCO1B1 pharmacogenetics variants in the Saudi population. This study provides a comprehensive overview of SLCO1B1 variation in Saudi individuals, one of the largest Arab populations in the Middle East. METHODS: The dataset of 11,889 (9,961 exomes and 1,928 pharmacogenetic gene panel) Saudi nationals, was used to determine the presence and frequencies of SLCO1B1 variants, as described by the Clinical Pharmacogenetic Implementation Consortium (CPIC).” | 0.95 | saudi_context_rules_v1 |
| variant | rs2306283 | “RESULTS: We identified 141 previously described SNPs, of which rs2306283 (50%) and rs4149056 (28%), were the most common.” | 0.90 | hgvs_regex_v1 |
The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing.
PMID 37222158 | PMCID PMC10242434 | DOI 10.2217/pgs-2023-0043 · Pharmacogenomics · 2023 · 8 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | rs4149056 | “Patients & methods: Repository DNA samples from 1064 women self-identifying as Filipino, Korean, Japanese, Native Hawaiian, Marshallese or Samoan and aged 18 years or older were used for targeted sequencing of three genetic variants (rs4149056, rs1799853 and rs1057910).” | 0.90 | hgvs_regex_v1 |
| gene | ABCG2 | “The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing.” | 0.98 | hgnc_dict_v1 |
| gene | SLCO1B1 | “The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing.” | 0.98 | hgnc_dict_v1 |
Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav-Related Liver Injury.
PMID 35754504 | PMCID PMC9214039 | DOI 10.3389/fphar.2022.882962 · Frontiers in pharmacology · 2022 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | rs4149056 | “This study presumed that SLCO1B1 may play a general role in the DILI susceptibility and therefore investigated the association of rs4149056 (SLCO1B1*5, T521C) polymorphism with flucloxacillin- and co-amoxiclav-induced liver injury.” | 0.90 | hgvs_regex_v1 |
| gene | SLCO1B1 | “Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav-Related Liver Injury.” | 0.98 | hgnc_dict_v1 |
| gene | SLCO1B3 | “Testing a different allele (SLCO1B1*1B) and another family member gene (SLCO1B3) may still be needed to provide a clearer role of SLCO1B drug transporters in DILI development-related to the chosen antimicrobials.” | 0.98 | hgnc_dict_v1 |
| variant | T521C | “This study presumed that SLCO1B1 may play a general role in the DILI susceptibility and therefore investigated the association of rs4149056 (SLCO1B1*5, T521C) polymorphism with flucloxacillin- and co-amoxiclav-induced liver injury.” | 0.82 | literature_variant_regex_v2 |